Natural Killer Cell Functional Activity After 4-1BB Costimulation

Inflammation

Volumn 38, Issue 3, 2015, Pages 1181-1190

  Navabi, Shadi sadat ^a   Doroudchi, Mehrnoosh ^a   Tashnizi, Ahmad Hosseini ^b   Habibagahi, Mojtaba ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CD137 (4 1BB); CD137 ligand (4 1BBL); costimulation; natural killer cell

Indexed keywords

CD137 LIGAND; CD56 ANTIGEN; FAS LIGAND; FASLG PROTEIN, HUMAN; GAMMA INTERFERON; GRANZYME; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NCAM1 PROTEIN, HUMAN; PERFORIN;

ADENOVIRIDAE; BIOSYNTHESIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GENETIC TRANSDUCTION; GENETICS; HUMAN; IMMUNOLOGY; K562 CELL LINE; LYMPHOCYTE ACTIVATION; MCF 7 CELL LINE; METABOLISM; NATURAL KILLER CELL; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

4-1BB LIGAND; ADENOVIRIDAE; ANTIGENS, CD56; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; GRANZYMES; HUMANS; INTERFERON-GAMMA; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MCF-7 CELLS; PERFORIN; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC;

EID: 84939978516     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-0082-0     Document Type: Article

References (30)

1. Inngjerdingen, M., L. Kveberg, C. Naper, and J.T. Vaage. 2011. Natural killer cell subsets in man and rodents. Tissue Antigens 78: 81–88.
2. Sun, J.C., S. Lopez-Verges, C.C. Kim, J.L. DeRisi, and L.L. Lanier. 2011. NK cells and immune “memory”. Journal of Immunology 186: 1891–1897.
3. Bryceson, Y.T., M.E. March, H.G. Ljunggren, and E.O. Long. 2006. Activation, coactivation, and costimulation of resting human natural killer cells. Immunology Reviews 214: 73–91.
4. Brigl, M., and M.B. Brenner. 2010. How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens. Seminars in Immunology 22: 79–86.
5. Long, E.O., H.S. Kim, D. Liu, M.E. Peterson, and S. Rajagopalan. 2013. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annual Review of Immunology 31: 227–258.
6. Gumbleton, M., and W.G. Kerr. 2013. Role of inositol phospholipid signaling in natural killer cell biology. Frontiers in Immunology 4: 47.
7. Ortaldo, J.R., and H.A. Young. 2003. Expression of IFN-gamma upon triggering of activating Ly49D NK receptors in vitro and in vivo: costimulation with IL-12 or IL-18 overrides inhibitory receptors. Journal of Immunology 170: 1763–1769.
8. Watts, T.H. 2010. Staying alive: T cell costimulation, CD28, and Bcl-xL. Journal of Immunology 185: 3785–3787.
9. Kinnear, G., N.D. Jones, and K.J. Wood. 2013. Costimulation blockade: current perspectives and implications for therapy. Transplantation 95: 527–535.
10. Scandiuzzi, L., K. Ghosh, and X. Zang. 2011. T cell costimulation and coinhibition: genetics and disease. Discovery Medicine 12: 119–128.
11. Habib-Agahi, M., T.T. Phan, and P.F. Searle. 2007. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. International Immunology 19: 1383–1394.
12. Kim, Y.J., M.K. Han, and H.E. Broxmeyer. 2008. 4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cells. Blood 111: 1378–1386.
13. Kim, Y.J., M.K. Han, and H.E. Broxmeyer. 2008. 4–1BB regulates NKG2D costimulation in human cord blood CD8+ T cells. Blood 111: 1378–1386.
14. Baessler, T., J.E. Charton, B.J. Schmiedel, F. Grunebach, M. Krusch, A. Wacker, et al. 2010. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 115: 3058–3069.
15. Choi, B.K., Y.H. Kim, C.H. Kim, M.S. Kim, K.H. Kim, H.S. Oh, et al. 2010. Peripheral 4-1BB signaling negatively regulates NK cell development through IFN-gamma. Journal of Immunology 185: 1404–1411.
16. Buechele, C., T. Baessler, B.J. Schmiedel, C.E. Schumacher, L. Grosse-Hovest, K. Rittig, et al. 2012. 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia. European Journal of Immunology 42: 737–748.
17. Wang, X., D.A. Lee, Y. Wang, L. Wang, Y. Yao, Z. Lin, et al. 2013. Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation. Clinical and Experimental Immunology 172: 104–112.
18. Melero, I., D. Hirschhorn-Cymerman, A. Morales-Kastresana, M.F. Sanmamed, and J.D. Wolchok. 2013. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clinical Cancer Research 19: 1044–1053.
19. Houot, R., H. Kohrt, and R. Levy. 2012. Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. Oncoimmunology 1: 957–958.
20. Wong, M.L., and J.F. Medrano. 2005. Real-time PCR for mRNA quantitation. Biotechniques 39: 75–85.
21. Wortzman, M.E., D.L. Clouthier, A.J. McPherson, G.H. Lin, and T.H. Watts. 2013. The contextual role of TNFR family members in CD8(+) T-cell control of viral infections. Immunology Reviews 255: 125–148.
22. So, T., and M. Croft. 2013. Regulation of PI-3-kinase and Akt signaling in T lymphocytes and other cells by TNFR family molecules. Frontiers in Immunology 4: 139.
23. Song, D.G., Q. Ye, C. Carpenito, M. Poussin, L.P. Wang, C. Ji, et al. 2011. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Research 71: 4617–4627.
24. Dowell, A.C., K.A. Oldham, R.I. Bhatt, S.P. Lee, and P.F. Searle. 2012. Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12. Cancer Immunology, Immunotherapy 61: 615–628.
25. St Rose, M.C., R.A. Taylor, S. Bandyopadhyay, H.Z. Qui, A.T. Hagymasi, A.T. Vella, et al. 2013. CD134/CD137 dual costimulation-elicited IFN-gamma maximizes effector T-cell function but limits Treg expansion. Immunology and Cell Biology 91: 173–183.
26. Fujisaki, H., H. Kakuda, N. Shimasaki, C. Imai, J. Ma, T. Lockey, et al. 2009. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Research 69: 4010–4017.
27. Shook, D.R., and D. Campana. 2011. Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens 78: 409–415.
28. Cho, D., D.R. Shook, N. Shimasaki, Y.H. Chang, H. Fujisaki, and D. Campana. 2010. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clinical Cancer Research 16: 3901–3909.
29. Milush, J.M., S. Lopez-Verges, V.A. York, S.G. Deeks, J.N. Martin, F.M. Hecht, et al. 2013. CD56negCD16(+) NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirology 10: 158.
30. Buechele, C., T. Baessler, S. Wirths, J.U. Schmohl, B.J. Schmiedel, and H.R. Salih. 2012. Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL). Leukemia 26: 991–1000.